Cardiff Oncology, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Cardiff Oncology's Q2 2026 report highlights ongoing litigation with NMS, substantial doubt about its going concern status, and a registered direct offering to raise capital, alongside promising clinical trial updates for onvansertib.
NASDAQ
Cardiff Oncology reports a reduced net loss in Q3 2025, driven by decreased R&D expenses, while its lead asset onvansertib continues to show promising clinical trial results in multiple cancer indications.
NASDAQ
10-Q: Cardiff Oncology Reports Increased Losses Amid Promising Clinical Trial Progress for Onvansertib
Cardiff Oncology's latest quarterly report reveals a significant increase in net loss and cash burn, while highlighting positive clinical data for its lead asset, onvansertib, across multiple cancer indications and securing a new patent.
NASDAQ
10-Q: Cardiff Oncology Reports First Quarter 2025 Financial Results and Provides Clinical Program Update
Cardiff Oncology's Q1 2025 report reveals increased R&D spending and a net loss, but the company believes it has sufficient cash to fund operations into Q1 2027.
NASDAQ
10-Q: Cardiff Oncology Reports Third Quarter 2024 Financial Results and Provides Clinical Program Update
Cardiff Oncology's Q3 2024 report details financial results, clinical trial progress, and a focus on their lead drug candidate, onvansertib.
NASDAQ
Cardiff Oncology's Q2 2024 report details financial results, clinical trial progress, and a focus on their lead drug candidate, onvansertib.
NASDAQ
Cardiff Oncology's first quarter 2024 results show a net loss of $10.0 million, with ongoing clinical trial advancements and a focus on their lead drug candidate, onvansertib.